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Objective: Angiogenesis is a critical step of breast cancer metastasis. Oncogenic Ras promotes the remodeling of
cancer microenviroment. Tumor-associated macrophages (TAMs) are a prominent inflammatory cell population
emerging in the microenviroment and facilitating the angiogenesis and metastasis. In the present study, we tried to
investigate the relationship between the expression of Ras and infiltration of TAM, both of which could further
promote angiogenesis.
Methods: Expressions of Ras, CD68 and CD34 were assessed by immunohistochemistry. The infiltration of
macrophages was evaluated by counting the number of CD68+ cells. Vessel endothelial cells were defined as CD34+
cells. Angiogenesis vascularity was defined by microvessel density (MVD) assay through counting the number of
vessels per field counted in the area of highest vascular density. The Kaplan–Meier survival analysis was used to
estimate the overall survival (OS). Macrophages were derived from monocytes in the presence of macrophage
colony-stimulating-factor (MCSF). Breast cancer cells were treated with macrophage-conditioned medium (MCM)
and tested the expressions of K-, H- and N-Ras by using realtime-PCR.
Results: Ras positive status was correlated with ER, PR and Her-2 positivity, larger tumour size and lymph node
metastasis, as well as higher TNM stages. A higher number of CD68+ cells was correlated with larger tumour size,
higher TNM stages and Her-2 positivity. Both Ras positivity and infiltration of CD68+ macrophages correlated with
poor OS. The number of CD68+ cells was positively correlated with the expression of Ras. Treatment with MCM did
not up-regulate but repressed the expression of Ras. Both up-regulation of Ras and infiltration of TAMs correlated
with increased MVD.
Conclusion: Expression of Ras and infiltration of TAM were positively correlated, and both participated in
angiogenesis. Elevated Ras could be responsible for the infiltration of TAM.
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Breast cancer is one of the most frequent causes of can-
cer mortality in females in developed countries. Al-
though early detection, precise resection using wide
margins, and systematic adjuvant therapy have improved
survival, recurrence and metastasis remains the leading
cause of breast cancer-related mortality [1-4].* Correspondence: mtao@medmail.com.cn
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unless otherwise stated.Angiogenesis, the process of forming new blood ves-
sels from existing vascular networks, is a critical event
which is essential for the growth and persistence of solid
tumors and their metastasis [5]. Data from experimental
and clinical studies indicate that breast cancer is an
angiogenesis-dependent tumor. It has been suggested
that the intensity of angiogenesis may be inversely corre-
lated with the time of survival of patients with invasive
breast cancer [6]. Several methods, such as visual vascular
grading, manual counting of microvessels in defined micro-
scopic field areas termed as microvessel density (MVD),
and the Chalkley counting method, have been applied to
quantify tumour vascularity by using immunostaining foris an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinicopathologic characteristics of tumour
Variable Number of patients (%)
Number of the patients 120
Length
<2 cm 12 (10%)








Estrogen receptor status (ER)
Negative 60 (50%)
Positive 60 (50%)




IHC negative (0 and 1+) 68 (56.67%)
IHC positive (2+ and 3+) 52 (43.33%)
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CD34 [7,8]. Many literatures have concluded that the MVD
assay, developed by Weidner et al. [9,10], is a reliable
method for investigating the prognostic value of angiogen-
esis in patients with breast cancer [8].
It has been increasingly recognized that tumor micro-
environment plays an important role in angiogenesis [11].
Tumor-associated macrophages (TAMs) are a prominent
inflammatory cell population in many tumor types resid-
ing in both perivascular and avascular, hypoxic regions of
these tissues. Analysis of TAMs in human tumor biopsies
has shown that they express a variety of tumor-promoting
factors and evidence from transgenic murine tumor
models has provided unequivocal evidence for the import-
ance of these cells in driving angiogenesis, lymphangio-
genesis, immunosuppression, and metastasis [12]. It has
been well accepted that TAMs are generally recruited
from blood monocytes by diverse chemokines such as
CCL2 (MCP-1), CCL5, CCL7, interleukin 8 (IL-8, CXCL8)
and CXCL12, followed by migration to diverse areas of the
tumor microenvironment and differentiation according to
surrounding cellular or environmental stimuli [13].
Ras protein family members, composed of K-, H- and
N-Ras, belong to a class of protein called small GTPase,
and are involved in cellular signal transduction. As these
signals result in cell growth and division, overactive Ras
signaling can ultimately lead to carcinogenesis [14]. Pre-
vious study proved that activation of oncogenic mutant
K-Ras could result in up-regulation of CCL2 (MCP-1)
[15]. Activation of Ras pathway also increased expression
of CCL5 [16,17]. Moreover, oncogenic Ras upregulates
the expression of IL-8 [14], while shRNA-mediated K-
Ras knockdown induced significant down-regulation of
IL-8 [18]. These investigations suggested that the recruit-
ment of TAM could be a consequence of activation of Ras
pathway. However, the relationship between Ras expres-
sion and TAM infiltration has not been investigated in
breast cancers. In the present study, we investigated the
association between TAM marker, CD68, and Ras expres-
sion in breast cancer specimens. The participation of
TAM and Ras in angiogenesis was also investigated.
Methods
Patients and tissue material
The material consisted of 120 female breast cancer pa-
tients whose tissue samples were available (mean age at
surgery was 51.4 years, range 30–82 years) and who
were operated and treated during 2007.01-2009.9. All
human tissue samples were obtained and handled in ac-
cordance with an approved Institutional Review Board
application (the Committee on Medical Ethics, the First
Affiliated Hospital of Soochow University). Tumour
characteristics were obtained from the pathology data-
base (Table 1). None of the patients received radiationor chemotherapy before operation. All breast tumours
were invasive carcinomas. All of the tumors were classi-
fied according to the International Union Against Can-
cer (UICC) tumor/lymph node/metastasis (TNM)
classification system [19]. Patients received systemic
adjuvant therapy after surgery according to NCCN
(National Comprehensive Cancer Network) breast can-
cer clinical practice guidelines [20]. Generally, patients
with low risk (Node-negative, ER/PR positive, T ≤ 1 cm,
grade 1, no lymphovascular invasion, Her-2/neu nega-
tive, age ≥ 35) received no adjuvant therapy or received
endocrine therapy only; patients with intermediate risk
(Node-negative and at least one of the following: T > 2 cm,
grade > 1, lymphovascular invasion, age < 35, Her-2/neu
positive; or one to three nodes positive and Her/2-neu
negative) received adjuvant chemotherapy, adjuvant
chemotherapy followed by endocrine therapy, or endo-
crine therapy only; patients with high risk (one to three
nodes positive and Her/2-neu positive; or ≥ four nodes
positive) received adjuvant chemotherapy, or adjuvant
chemotherapy followed by endocrine therapy. The adju-





TC (Docetaxel/cyclophosphamide), AC→T (Doxorubicin/
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H (Doxorubicin/cyclophosphamide, followed by paclitaxel
plus trastuzumab). Patients who suffered from tumor
recurrence received palliative chemotherapy by using
single agents or combination regimens. Single agents
included doxorubicin, paclitaxel, capecitabine, gemci-
tabine, vinorelbine, and cisplatin. Combination regi-
mens included FAC/CAF (Fluorouracil/doxorubicin/
cyclophosphamide), FEC/CEF (Fluorouracil/epirubicin/
cyclophosphamide), AC (Doxorubicin/cyclophosphamide),
EC (epirubicin/cyclophosphamide), CMF (Cyclophospha-
mide/methotrexate/fluorouracil), GT (gemcitabine/pac-
litaxel). Application of trastuzumab depended on Her-2
status. Patients were followed regularly for 5 years. The
prognostic analyses were performed regarding overall
survival (OS).
Immunohistochemistry
All resection specimens in this study were fixed in 10%
buffered formalin and paraffin embedded by routinely
processing. Sections were cut at a thickness of 4 μm,
heated at 60°C for 30 min, then deparaffinized and hy-
drated through a series of xylene and alcohol baths be-
fore staining. The slides were microwaved with antigen
retrieval solution (citrate buffer, pH 6.0, containing 0.3%
trisodium citrate and 0.04% citric acid) for 5 min. After
replenishment of this solution, the slides were micro-
waved again for an additional 5 min and then allowed to
cool for 20 min. The sections were then rinsed in PBS
(phosphate-buffered saline), and immersed in 3% H2O2
for 15 minutes to block the endogenous peroxidase.
Thereafter, the sections were incubated with 10% BSA
(bull serum albumin) at room temperature for 60 minutes
to block nonspecific antibodies. Immunohistochemical
staining was performed with rabbit anti-Ras antibody
(Abcam, ab108602), mouse anti-CD68 antibody (Abcam,
ab49777), or rabbit anti-CD34 antibody (Abcam, ab81289)
respectively at room temperature for 2 h. After incubation
with the corresponding secondary antibodies for 20 min,
the bound complex was visualized by using the SuperPic-
Ture polymer detection kit (No.87-8963; Invitrogen).
Evaluation of immunostaining
All the staining results were evaluated by two independ-
ent researchers. All analyses were performed blind with
respect to the clinical outcomes. A positive stain for Ras
was defined as brown stain seen in the cytoplasm.
The infiltration of macrophages was evaluated by count-
ing the number of CD68+ cells as previously described [21].
Briefly, the five most representative high-power fields (×400
magnification) per slide were selected. Tumour-infiltrating
macrophages were large irregular cells with oval to round
nuclei and fine processes that showed strong cytoplasmic
staining (sometimes granular) but no nuclear staining forCD68. The number of CD68+ nucleated cells was counted
manually and expressed as cells per mm2. To evaluate the
validity of the analysis, the area measurement and counting
were repeated 4 weeks later.
Angiogenesis vascularity was defined as the number of
vessels per field counted in the area of highest vascular
density, termed as microvessel density (MVD) [9,10].
Endothelial cells were marked with anti-CD34 antibody.
CD34 antigen was localized in the cytoplasm and cellu-
lar membrane of vascular endothelial cells. Single endo-
thelial cells, endothelial cell clusters, and microvessels in
the tumors, clearly separated from adjacent microvessels,
were counted. Peritumoral vascularity and vascularity in
areas of necrosis were not scored. A vascular lumen was
not a requirement for a structure to be counted as a
microvessel. Branching structures were counted as one,
unless there was a break in the continuity of the vessel,
in which case it was counted as two distinct vessels.
Areas with a higher density of CD34+ cells and cell clus-
ters relative to adjacent areas were classified as ‘hot
spots’. The slides were initially screened at low power to
identify the areas with the highest number of microves-
sels or vascularity hot spots. Microvessels were counted
in 400× magnification fields. MVD was defined as the
number of manually counted vessel profiles per mm2
taken as the average from the three hot-spot counts.
Cell culture
MCF-7 and MDA-MB-231 breast cancer cells were ob-
tained from American Type Culture Collection (Manassas,
VA, USA) and maintained in RPMI-1640 (Gibco, Grand
Island, NY, USA) medium supplemented with 10% fetal
calf serum (FCS; Hyclone, Logan, UT, USA), 100 U/ml
penicillin and 100 mg/ml streptomycin at 37°C in a hu-
midified atmosphere with 5% CO2. The cells were pas-
saged every 2–3 days to maintain exponential growth.
Macrophage preparation and culture
Buffy coats that contain mononuclear cells were col-
lected from the blood of healthy individual donors at the
First Affiliated Hospital of Soochow University with an
approved Institutional Review Board application (the
Committee on Medical Ethics, the First Affiliated Hospital
of Soochow University). Primary blood monocytes were
isolated by density-gradient centrifugation through Ficol/
Hypaque (Amersham Bioscience, Piscataway, NJ), sus-
pended (8 × 106 cells/ml) in DMEM medium (Gibco) with
10% heat-inactivated human serum (Sigma, St. Louis,
MO), and seeded in culture dishes. After incubation for
2 h at 37°C, adherent cells were cultured in medium sup-
plemented with 40 ng/ml human MCSF (PeproTech Inc,
Rocky Hill, NJ). Cells were allowed to differentiate for
7 days in the presence of MCSF. On day 7, fresh medium
without MCSF was added to the cells, and the cells
Table 2 Ras expression in various stages
Stage n Ras positive Ras negative Positive rate (%)
I 8 2 6 20.00
II 73 40 33 54.79
III 39 35 4 89.74
Chi-square value = 19.22, P <0.0001.
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collected, centrifuged, stored in aliquots at −80°C, and
defined as macrophage-conditioned medium (MCM).
Real-time PCR
Total RNA was extracted using Trizol reagent (Invitrogen,
Valencia, CA, USA) according to the manufacturer’s
protocol. After spectrophotometric quantification, 1 μg of
total RNA in a final volume of 20 μl was used for reverse
transcription with AMV reverse transcriptase (Promega,
WI, USA) according to the manufacturer’s protocol. Ali-
quots of cDNA, which corresponded to equal amounts of
RNA, were used for the quantification of mRNA by real-
time PCR using a TL988 Real-time Quantitative PCR
Detection System (TianLong Science and Technology,
Xi’An, Shanxi, China). The reaction system (20 μl) con-
tained the corresponding cDNA, forward and reverse
primers, and SYBR Green PCR master mix (Roche, Indy,
IN, USA). All the data were analyzed using β-actin gene
expression as an internal standard. The specific primers
were as follows: (1) K-Ras: forward, 5′-AGAGTGCCTTG
ACGATACAGCT-3′, reverse, 5′-CAGTCCTCATGTACT
GGTCCCTC-3′, product, 177 bp; (2) H-Ras: forward, 5′-C
ACCAGTACAGGGAGCAGATCA −3′, reverse, 5′-TGAG
CCTGCCGAGATTCCA-3′, product, 113 bp; (3) N-Ras:
forward, 5′-TACATGAGGACAGGCGAAGG-3′, reverse,
5′-TGGCAATCCCATACAACCCT-3′, product, 345 bp;
and (4) β-actin: forward, 5′-TCATGAAGTGTGACGTGG
ACAT-3′, reverse, 5′-CTCAGGAGGAGCAATGATCTT
G-3′, product, 158 bp.
Statistical analysis
Each experiment was performed at least in triplicate. Stat-
istical analysis was performed using SAS 9.2 software
(SAS Institute Inc., Cary, NC, USA). The correlations be-
tween Ras, CD68+ cell infiltration and clinicopathologic
features were analyzed using Spearman’s rank test. The as-
sociation between CD68+ cell number and MVD numbers
were also performed using Spearman’s rank test. Chi-
square tests were used for comparison of Ras expression
in various stages. For analysis of survival data, Kaplan–
Meier curves were constructed, and statistical analysis was
carried out using the log-rank test. OS was defined as the
time from beginning of surgery to death from any cause
or the last date of follow-up. For the Ras gene expression
data, statistical analyses were carried out with unpaired
Student’s t-test. All values of P < 0.05 were considered sta-
tistically significant, and all tests were two-sided.
Results
Ras expressions is associated with clinical outcomes in
breast cancers
Among the 120 samples, Ras could be detected in 77
specimens (64.17%). In particular, the Ras positive ratewas 20.00% for patients with stage I disease, compared
with 54.79% for patients with stage II and 89.74% for
patients with stage III disease (P <0.0001, Table 2).
Moreover, a Ras positive status was correlated with ER,
PR and Her-2 positivity, larger tumour size and lymph
node metastasis, as well as higher TNM stages. Other
histological features had no statistically significant asso-
ciation with Ras expression (Table 3). As shown in
Figure 1B, positivity of Ras correlated with poor OS,
suggesting the Ras status was an independent prognos-
tic factor for survival.
Infiltration of CD68+ macrophages predict outcomes in
breast cancers
Infiltration of macrophage was evaluated using CD68
staining. CD68+ cells could be detected in 116 speci-
mens (96.67%), with an average number of 20.44 and a
median number of 11.6. Correlations between macro-
phage density and clinicopathological features were
then analyzed. A higher number of CD68+ cells was cor-
related with larger tumour size, higher TNM stages and
Her-2 positivity. Other histological features had no sta-
tistically significant association with CD68+ cell infiltra-
tion (Table 3).
As shown in Figure 2B, infiltration of CD68+ macro-
phages correlated with poor OS, suggesting the enrich-
ment of macrophage is predictive of poor prognosis and
reduced survival in human breast cancer.
Relationship between expressions of Ras and infiltration
of CD68+ macrophages
The correlation between the expression of Ras and the
number of CD68+ cells was than analyzed. The number
of CD68+ cells in Ras negative group was 12.05 ± 18.44,
compared with 25.13 ± 24.43 in Ras positive group. The
number of CD68+ cells was positively correlated with
the expression of Ras (r = 0.326, P = 0.000292).
To find out the influence of macrophage on the ex-
pression of Ras, we treated breast cancer cells with
macrophage-conditional medium (MCM), and evalu-
ated the expression of K-Ras, N-Ras and H-Ras using
Realtime-PCR. Expression of N-Ras was not found in
MDA-MB-231 cells. As shown in Figure 3, treatment
with MCM had no effects on the expressions of K-Ras
or H-Ras in MDA-MB-231 cells. MCM had no effects




Correlation coefficient P value Correlation coefficient P value Correlation coefficient P value
Age −0.00524 0.955 −0.0861 0.349 −0.172 0.0599
Long diameter 0.396 0.00000879 0.355 0.0000777 0.168 0.0667
Tumor volume 0.513 0.00000000259 0.468 0.0000000938 0.393 0.0000104
Lymph node metastasis 0.348 0.000109 0.170 0.0633 0.000 1.000
TNM 0.400 0.00000714 0.263 0.00382 0.186 0.0418
ER 0.191 0.0366 −0.167 0.0689 0.233 0.0104
PR 0.227 0.0129 −0.0933 0.310 0.392 0.0000110
Her-2 0.303 0.000812 0.303 0.000814 0.101 0.272
Figure 1 Effects of of Ras expression on overall survival in breast cancers. (A) Expression of Ras in breast cancers. (B) Kaplan—Meier plot of
overall survival (OS) stratified by Ras expression.
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Figure 2 Effects of of CD68+ cell infiltration on overall survival in breast cancers. (A) Infiltration of CD68+ cells in breast cancers. (B) Kaplan—
Meier plot of overall survival (OS) stratified by CD68+ cell infiltration.
Figure 3 Relationship between expressions of Ras and infiltration of CD68+ cells. (A) The association of Ras expression and CD68+ cells
infiltration in breast cancer cells. (B)-(F) Expression of K-, H- and N-Ras in macrophage-conditional medium (MCM) treated MDA-MB-231 and MCF-
7 cells. **P < 0.01 indicates significant differences from control group.
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pressed the expressions of K-Ras and N-Ras in MCF-7
cells. Thus, the infiltration of macrophage might be a
negative regulator on the expression of Ras.
Overexpression of Ras and infiltration of CD68+
macrophages correlated with angiogenesis
Angiogenesis vascularity was defined by MVD assay as
previously described [9,10]. CD34 could be detected in
all the 120 specimens. All endothelial cells in the tissue
were positively stained by CD34 antibodies. The area of
greatest vascular density was usually, but not always, at
the periphery of the carcinoma. MVD ranged from 4 to
129, with a mean of 46.83. A higher MVD number was
correlated with larger tumour size, higher TNM stages,
ER positivity and PR positivity. Other histological features
had no statistically significant association with MVD num-
ber (Table 3). The number of MVD in Ras negative group
was 31.77 ± 28.71, compared with 55.25 ± 23.33 in Ras
positive group (r = 0.451 P = 0.000000299, Figure 4B).
Moreover, with regard to the correlation between CD68+
cells and MVD, there was a statistically significant correl-
ation between increased number of CD68+ cells and in-
creased MVD (r = 0.288 P = 0.00146, Figure 4C), indicating
the up-regulation of Ras and the infiltration of CD68+ mac-
rophages correlated with angiogenesis.
Disscussion
The Ras family of small guanosine triphosphatases
(GTPases), composed of K-, H- and N-Ras, normally
transmit signals from cell surface receptors to the interior
of the cell. Stimulation of cell surface receptors leads to
the activation of guanine exchange factors (GEFs), which,
in turn, convert Ras from an inactive GDP-bound state to
an active GTP-bound state. In this active state, Ras adopts
a conformation that permits effector proteins such as
phosphoinositide 3-kinases (PI3Ks), the Rafs mitogen-
activated protein kinase kinase kinases, and RalGEFs to
bind Ras, leading to their activation and propagation of
signaling. This signal is terminated by GTPase-activating
proteins (GAPs) that stimulate the GTPase activity of Ras,
returning Ras to its inactive GDP-bound state [14].
In most cancers, Ras is inappropriately activated. In
fact, 20–30% of all tumors harbor oncogenic point mu-
tations in Ras at Gly12, Gly13, or Gln61 that impair the
intrinsic and GAP stimulated GTP hydrolysis, leaving
oncogenic Ras in a constitutively active GTP-bound
state [22]. If Ras itself is not mutated, often Ras signaling
pathway components are inappropriately activated or re-
pressed to promote Ras signaling. Specifically, upstream
cell surface receptors that activate Ras, such as epidermal
growth factor receptor (EGFR) and the closely related
Her-2/Neu, are often amplified or mutated to remain ac-
tive, resulting in chronic Ras activation [14]. In fewercases, there is a loss of a GAP, keeping Ras in an active,
GTP-bound state [14]. Additionally, downstream activat-
ing mutations in Raf and PI3K or loss of the lipid phos-
phatase PTEN leads to activation of individual Ras
effector pathways [14]. Furthermore, expression of Ras
was found to be up-regulated in breast cancers [23]. Thus,
the Ras pathway could be inappropriately activated in
multiple manners.
Tumor-associated macrophage (TAM) represent the
major inflammatory component of the stroma of many
tumors, able to affect different aspects of the neoplastic
tissue [24]. In the tumor microenvironment neoplastic
cells shape the differentiation and functional orientation
of TAM which, in turn, express several protumoral func-
tions, including secretion of growth factors and matrix-
proteases, promotion of angiogenesis and suppression of
adaptive immunity [18]. The protumoral role of TAM in
cancer is further supported by clinical studies that found a
correlation between the high macrophage content of tu-
mors and poor patient prognosis and by evidence showing
that long-term use of non-steroidal anti-inflammatory
drugs reduces the risk of several cancers [24].
In the present study, we found the association between
Ras expression and TAM infiltration by using immuno-
histochemistry. Mechanically, TAMs are generally re-
cruited from blood monocytes by diverse chemokines
such as CCL2 (MCP-1), CCL5, CCL7, CXCL8 and
CXCL12, migrate to diverse areas of the tumor micro-
environment and differentiate according to surrounding
cellular or environmental stimuli [13]. Previous study
proved that activation of Ras could result in up-
regulation of CCL2 (MCP-1) [15], CCL5 [16,17] and IL-
8 [14,18], the widely accepted cytokines participating in
the recruitment of monocyte, suggesting the overexpres-
sion of Ras could be the stimulation of TAM infiltration.
Could overexpression of Ras also be the consequence of
TAM infiltration? To verify this hypothesis, we treated
breast cancer cells with macrophage-conditional
medium (MCM) and evaluate expression of Ras. Inter-
estingly, treatment of MCM repressed Ras expression,
rather than overexpressing. Thus, it seems that the over-
expression of Ras might not be the consequence of
TAM infiltration. The findings in the present study sup-
ported the hypothesis that overexpresssion of Ras in
breast cancers might recruit infiltration of TAM, which
could further promote angiogenesis and cancer progres-
sion. Taking together, based on our present investigation
and previous studies, we speculated that the infiltration
of TAM is probably the consequence but not the in-
ducement of overexpressed Ras.
Angiogenesis (or neovascularization) consists in the
formation of new blood vessels from the endothelium
of the existing vasculature. It has been demonstrated
experimentally that tumor cell proliferation and growth,
Figure 4 Association of Ras and CD68+ cells in angiogenesis. (A) Expression of CD34 in breast cancer cells. (B) Association of Ras expression
with MVD number. (C) Association of CD68+ cell number with MVD numbers.
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the formation of new blood vessel [6]. When a new tumor
reaches the size of 1–2 mm, its ulterior growth re-
quires the induction of new blood vessels, which mayconsequently lead to the development of metastases,
via the penetration of malignant cells into the circula-
tion [8]. Consequently, angiogenic determination could
provide complementary information to that obtained from
Li et al. Cancer Cell International  (2015) 15:17 Page 9 of 10the tumor biological profile and could thus be used for
prognostic assessment and as a therapeutic target in hu-
man tumors [25,26]. Quantification of angiogenesis, using
microvessel density (MVD) as a parameter, is considered
to be a valuable prognostic indicator of breast cancer ag-
gressiveness [27]. Tumour vascularity in invasive breast
carcinoma has been extensively investigated in relation to
its prognostic significance. Increasing research in angio-
genesis has left little doubt about its importance in tumor
growth and metastatic dissemination [27].
Both activation of Ras and infiltration of TAM have
been found to contribute to the angiogenesis. Expression
of oncogenic Ras in tumor cells promotes survival of
endothelial cells, while loss of Ras expression triggered
apoptosis in endothelial cells, collapse in tumor vascula-
ture, and regression of the tumor [28]. Moreover, Ras
promotes transcription of vascular endothelial growth
factor (VEGF), a key factor promoting angiogenesis [29].
Ras also upregulates the expression of the cytokines IL-8
and IL-6, both of which promote angiogenesis [22].
Macrophages can exert a dual influence on blood ves-
sel formation and function. In general, as for interaction
with neoplastic cells, the pro-angiogenic functions of
TAM prevail. In several studies, TAM accumulation has
been associated with angiogenesis and with the produc-
tion of angiogenic factors such as VEGF and platelet-
derived endothelial cell growth factor. TAM tends to ac-
cumulate in hypoxic regions of tumors. A number of
pro-angiogenesis molecules have been shown to be
expressed by macrophage in low oxygen conditions,
such as VEGF, TNF-α and IL-8. Therefore, macrophages
recruited in situ represent an indirect pathway of ampli-
fication of angiogenesis, in concert with angiogenic
molecules directly produced by tumor cells [24].
In conclusion, inflammatory microenvironment has
been proved to promote cancerous angiogenesis. Previ-
ous studies have proved the relationship between onco-
genic Ras and angiogenesis, as well as the association
between infiltration of TAM and neovascularization.
Our present study found the link between oncogenic
Ras, infiltration of TAM and formation of neovasculari-
zation. Thus, our investigation provided a new hypoth-
esis to reveal the mechanism involved in the oncogenic
Ras modified inflammatory microenvironment which
further promotes angiogenesis and cancer progression.Abbreviations
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